Saby George

21.7k total citations · 3 hit papers
170 papers, 5.0k citations indexed

About

Saby George is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Saby George has authored 170 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Pulmonary and Respiratory Medicine, 98 papers in Oncology and 42 papers in Surgery. Recurrent topics in Saby George's work include Renal cell carcinoma treatment (91 papers), Cancer Immunotherapy and Biomarkers (67 papers) and Bladder and Urothelial Cancer Treatments (39 papers). Saby George is often cited by papers focused on Renal cell carcinoma treatment (91 papers), Cancer Immunotherapy and Biomarkers (67 papers) and Bladder and Urothelial Cancer Treatments (39 papers). Saby George collaborates with scholars based in United States, United Kingdom and France. Saby George's co-authors include Brian I. Rini, Robert J. Motzer, Hans J. Hammers, Elizabeth R. Plimack, David F. McDermott, Ulka N. Vaishampayan, Ian M. Waxman, Toni K. Choueiri, Timothy M. Kuzel and Bruce G. Redman and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Saby George

157 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

2014 865 citations Robert J. Motzer, Brian I. Rini et al. Journal of Clinical Oncology profile →
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial

2020 347 citations Laurence Albigès, Nizar M. Tannir et al. ESMO Open profile →
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial

2018 274 citations Michael B. Atkins, Elizabeth R. Plimack et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Saby George United States	30	3.3k	2.8k	1.4k	966	939	170	5.0k
Allen Lee Cohn United States	38	4.7k 1.4×	2.4k 0.8×	1.5k 1.1×	1.3k 1.3×	875 0.9×	159	6.9k
P. Koralewski Poland	23	4.5k 1.4×	3.5k 1.2×	2.1k 1.5×	1.7k 1.8×	926 1.0×	58	7.1k
Laura S. Wood United States	29	2.3k 0.7×	3.1k 1.1×	2.2k 1.6×	1.4k 1.5×	525 0.6×	99	4.9k
Ihor Vynnychenko Ukraine	21	4.6k 1.4×	4.3k 1.5×	1.4k 1.1×	901 0.9×	1.4k 1.5×	57	7.0k
Neeraj Agarwal United States	34	1.6k 0.5×	3.4k 1.2×	1.9k 1.4×	1.4k 1.4×	1.1k 1.2×	207	4.8k
Nobuaki Matsubara Japan	28	2.3k 0.7×	3.5k 1.2×	878 0.6×	1.1k 1.2×	1.1k 1.2×	233	5.6k
Jonathan Polikoff United States	25	2.5k 0.8×	2.0k 0.7×	694 0.5×	909 0.9×	781 0.8×	70	4.7k
Mark Kozloff United States	36	3.2k 1.0×	1.7k 0.6×	1.3k 1.0×	702 0.7×	612 0.7×	125	4.7k
Jean-Pascal Machiels Belgium	18	2.0k 0.6×	2.4k 0.9×	960 0.7×	848 0.9×	457 0.5×	36	4.5k
Martin H. Voss United States	40	2.6k 0.8×	4.0k 1.4×	3.1k 2.3×	2.0k 2.1×	906 1.0×	219	6.1k

Countries citing papers authored by Saby George

Since Specialization

Citations

This map shows the geographic impact of Saby George's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Saby George with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Saby George more than expected).

Fields of papers citing papers by Saby George

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Saby George. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Saby George. The network helps show where Saby George may publish in the future.

Co-authorship network of co-authors of Saby George

This figure shows the co-authorship network connecting the top 25 collaborators of Saby George. A scholar is included among the top collaborators of Saby George based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Saby George. Saby George is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Friedlander, Terence W., Peter H. O’Donnell, Daniel P. Petrylak, et al.. (2025). 3074P EV-103 Cohort K: Efficacy and safety of enfortumab vedotin (EV) with or without pembrolizumab (P) in cisplatin (cis)-ineligible pts with previously untreated locally advanced or metastatic urothelial cancer (la/mUC) with a median (m) follow-up (FU) of ≈3.5 y. Annals of Oncology. 36. S1487–S1488.

Higano, Celestia S., Sabina Dizdarevic, John Logue, et al.. (2024). Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE). Cancer. 130(11). 1930–1939. 4 indexed citations

George, Saby, María T. Bourlon, Jennifer Lord‐Bessen, et al.. (2024). Health-related quality of life (HRQoL) with nivolumab (NIVO) subcutaneous (SC) or intravenous (IV) in patients (pts) with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior therapy in the phase 3 CheckMate 67T trial.. Journal of Clinical Oncology. 42(16_suppl). 4535–4535. 1 indexed citations

Motzer, Robert J., Camillo Porta, Masatoshi Eto, et al.. (2024). Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.. Journal of Clinical Oncology. 42(16_suppl). 4504–4504. 7 indexed citations

Powles, Thomas, Mauricio Burotto, Bernard Escudier, et al.. (2024). Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial. ESMO Open. 9(5). 102994–102994. 31 indexed citations

Atkins, Michael B., Pooja Ghatalia, Jaime R. Merchan, et al.. (2024). Belzutifan in patients with advanced clear cell renal cellcarcinoma (ccRCC): Subgroup analysis of the phase 2 LITESPARK-013 study.. Journal of Clinical Oncology. 42(16_suppl). 4534–4534. 1 indexed citations

Shariftabrizi, Ahmad, Shalin Kothari, Saby George, et al.. (2023). Optimization of Radium-223 Treatment of Castration-resistant Prostate Cancer Based on the Burden of Skeletal Metastasis and Clinical Parameters. The Oncologist. 28(3). 246–251. 2 indexed citations

Roy, Arya Mariam & Saby George. (2023). Emerging resistance vs. losing response to immune check point inhibitors in renal cell carcinoma: two differing phenomena. Cancer Drug Resistance. 6(3). 642–55. 7 indexed citations

Petrylak, Daniel P., Bernhard J. Eigl, Saby George, et al.. (2023). Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of AGS15E Monotherapy in Patients with Metastatic Urothelial Carcinoma. Clinical Cancer Research. 30(1). 63–73. 2 indexed citations

10.

Shah, Neal, Matthew T. Campbell, Shifeng Mao, et al.. (2023). 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. Annals of Oncology. 34. S1016–S1017.

11.

Rini, Brian I., Sabina Signoretti, Toni K. Choueiri, et al.. (2022). Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Journal for ImmunoTherapy of Cancer. 10(12). e005445–e005445. 42 indexed citations

12.

Yamauchi, Takayoshi, Toshifumi Hoki, Takaaki Oba, et al.. (2021). T-cell CX3CR1 expression as a dynamic blood-based biomarker of response to immune checkpoint inhibitors. Nature Communications. 12(1). 1402–1402. 102 indexed citations

13.

Higano, Celestia S., Sabina Dizdarevic, Santhanam Sundar, et al.. (2021). 593P Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 32. S640–S641. 2 indexed citations

14.

Martini, Jean-François, Elizabeth R. Plimack, Toni K. Choueiri, et al.. (2020). Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research. 26(21). 5598–5608. 16 indexed citations

15.

McGregor, Bradley A., Michael S. Gordon, Ronan Flippot, et al.. (2020). Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational New Drugs. 38(6). 1807–1814. 24 indexed citations

16.

Zheng, Ying, Tongtong Yu, Jill Dreyfus, et al.. (2019). PCN171 COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS). Value in Health. 22. S469–S469.

17.

Пили, Роберто, David I. Quinn, Hans J. Hammers, et al.. (2017). Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clinical Cancer Research. 23(23). 7199–7208. 76 indexed citations

18.

George, Saby, et al.. (2015). Anti-Androgen Therapies for Prostate Cancer: A Focused Review. 11(2). 9 indexed citations

19.

Motzer, Robert J., Brian I. Rini, David F. McDermott, et al.. (2014). Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. Journal of Clinical Oncology. 33(13). 1430–1437. 865 indexed citations breakdown →

20.

George, Saby, Shetal N. Shah, & Ronald M. Bukowski. (2010). Stable Disease in Renal Cell Carcinoma After Using Signal Transduction Inhibitors. Reviews on Recent Clinical Trials. 5(2). 117–122. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact